NN9662 (Triple)
NNC0662-0419 · Novo Nordisk
A triple agonist pairing GLP-1 and GIP signaling with amylin rather than glucagon.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: Novo Nordisk lists NN9662 in Phase 2 for obesity.
Next: Public obesity efficacy data and trial details.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies2 records
NCT07639021
Weight managementObesity program; public efficacy results were not identified in the reviewed sources.
NN9662 · obesity dose-finding
Weight managementPhase 2 obesity dose-finding study; active, not recruiting. Separate from dose-escalation NCT07639021.
Related conditions and outcomes
Phase 2 studies1 record
NN9662 · type 2 diabetes
Glycemic control in type 2 diabetesSeparate Phase 2 study in type 2 diabetes; registry recruiting.
